Abstract
40 patients with advanced non-small cell lung cancer not previously treated were included in a study at phase II with vinorelbine 20 mg/Sq.m days 1 and 8, etoposide 60 mg/sq.m days 1-3 and cisplatin 75 mg/sq.m day 1 each 28 days for 6 cycles. There were 31 men and 9 women, being the average age of 54 years, with "performance Status" grade 0-2. All of them could be evaluated for toxicity and 31 for responsiveness. 10 patients were in stage IIIb and 21 at stage IV. 42% of objective responses were obtained and an overall survival of 9 months, which justifies further studies.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Cisplatin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / mortality
-
Male
-
Middle Aged
-
Vinblastine / administration & dosage
-
Vinblastine / analogs & derivatives
-
Vinorelbine
Substances
-
Antineoplastic Agents, Phytogenic
-
Vinblastine
-
Etoposide
-
Cisplatin
-
Vinorelbine